4.5 Article Proceedings Paper

Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans

期刊

VACCINE
卷 27, 期 36, 页码 4905-4911

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.06.036

关键词

Clinical trial; Tularemia vaccine; Live vaccine strain; Safety and immunogenicity

资金

  1. NIAID NIH HHS [N01AI30028, N01AI25465, N01-AI-25465, N01 AI025465, N01-AI-30028] Funding Source: Medline

向作者/读者索取更多资源

We evaluated the safety, reactogenicity and immunogenicity of escalating doses of a new Francisella tularensis Live Vaccine Strain (LVS) lot by scarification (SCAR) or subcutaneously (SQ) in humans. Subjects (N = 10/group) received one dose of LVS via SCAR at 10(5),10(7) or 10(9) cfu/ml or SQ at 10(2), 10(3), 10(4) or 10(5) cfu/ml; 14 subjects received placebo. All doses/routes were well tolerated. When compared to placebo, vaccination with 10(7) SCAR and 10(9) SCAR resulted in significantly higher serologic response frequencies, as measured by ELISA for IgG, IgM, IgA and microagglutination; whereas vaccination with 10(5) SCAR, 10(7) SCAR 10(9) SCAR and 10(5) SQ elicited a significantly higher interferon-gamma response frequency. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据